Trial Profile
ATOP Trial: Adjuvant Ado-Trastuzumab Emtansine (T-DM1) for Older Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab emtansine (Primary)
- Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms ATOP TRIAL
- 31 Jul 2019 Planned End Date changed from 31 Jan 2022 to 16 Mar 2022.
- 27 Jul 2018 Planned End Date changed from 1 Jan 2022 to 31 Jan 2022.
- 27 Jul 2018 Planned primary completion date changed from 1 Jan 2022 to 31 Jan 2022.